Drug intelligence / Profile preview

anti-amyloid beta peptide antibody

Development stage: Preclinical
Lead developer: Immunas Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Anti-amyloid beta peptide antibody is a monoclonal antibody currently in preclinical development by OncoTherapy Sciences for the treatment of Alzheimer's disease and dementia. The therapeutic is designed to target amyloid beta (Aβ) peptides, which are central to the amyloid cascade hypothesis of Alzheimer's pathogenesis. By binding to these peptides, the antibody aims to facilitate the clearance of amyloid plaques or neutralize toxic soluble amyloid species, thereby potentially preventing neurodegeneration and cognitive decline.

Other names: Anti-amyloid beta peptide antibody

Targets

Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on anti-amyloid beta peptide antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-amyloid beta peptide antibody.

Explore the full profile